Clinical Trials Browser

Phase 2 × avelumab × Clear all

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT05947500 2026-04-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2 Active not recruiting

Carcinoma, Merkel Cell

NCT04291885 2026-04-09

I-MAT

Phase 2 Active not recruiting

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT05327686 2026-04-08

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT03076554 2026-04-07

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Phase 2 Active not recruiting

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT06228066 2026-03-23

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT03006848 2026-02-23

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Phase 2 Completed

19 enrolled 11 charts

Osteosarcoma

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Phase 2 Active not recruiting

Skin Neoplasms

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03744793 2026-01-09

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT06518564 2026-01-07

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Phase 2 Recruiting

Endometrial Neoplasms

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Phase 2 Active not recruiting

Neoplasm Metastasis, Penile Neoplasms

NCT05419362 2025-12-16

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Urinary Bladder Neoplasms

NCT06557278 2025-10-21

COMUNITY

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT04258956 2025-09-11

AXAGIST

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Endometrial Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 2 Active not recruiting

100 enrolled 15 charts

Breast Neoplasms

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03357757 2025-06-26

LATENT

Phase 2 Completed

GastrointestinalLymphoid

Cancer That is Associated With a Chronic Viral Infection

NCT03971409 2025-05-02

InCITe

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

Neoplasms, Second Primary

NCT06892860 2025-03-25

DISCUS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT06869473 2025-03-14

AVEC-119

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03674424 2025-02-26

AURA

Phase 2 Completed

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2 Active not recruiting

48 enrolled 13 charts

Breast Neoplasms

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Phase 2 Completed

Recurrence

NCT04513951 2025-01-09

AVETRIC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT04068831 2024-12-27

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Phase 2 Completed

18 enrolled 9 charts

Carcinoma, Renal Cell

NCT03278379 2024-12-24

NET-002

Phase 2 Completed

Neuroendocrine Tumors

NCT03990571 2024-10-18

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Phase 2 Completed

40 enrolled 13 charts

Carcinoma, Adenoid Cystic, Disease Progression

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell